直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • 联邦巡回法院知识产权博客
    • INCONTESTABLE® Blog
    • Prosecution First博客
  • Events & Webinars
  • 知识产权讯息
  • 播客
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

A Summary of the Supreme Court’s Stanford v. Roche Molecular Systems, Inc. Decision

June 8, 2011

By Erika Harmon Arner

This week, the Supreme Court issued its decision in Stanford v. Roche Molecular Systems, Inc., holding that the Bayh-Dole Act, which allows federal contractors to “elect to retain title” to patents developed with federal money, does not automatically vest contractors with patent rights to federally funded inventions or otherwise authorize contractors to unilaterally take title to such inventions. The Court stated that the premise that rights to an invention belong to the inventor holds here, as the language of the Act did not clearly intend to modify this background premise.

In this case, Stanford had been granted rights to the patents at issue by assignment, but those patents were subject to a side agreement an inventor had made with a third party research facility due to the lower court’s interpretation of the contract provisions the inventor had signed with each. The Court noted that federal contractors generally obtain assignments from their employees, as do most employers, and that effective assignment practice would grant contractors such rights, as intended in the Act, without the need for disrupting basic patent law principles.

Stanford v. Roche Molecular Systems, Inc. Supreme Court Decision, 6.6.2011

 

Related Practices

上诉、争议和法律策略

联邦巡回法院和最高法院上诉

Related Industries

生命科学

生物技术

Related Professionals

Erika Harmon Arner
合伙人
Washington, DC
+1 571 203 2754
Email

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Conference

Atlantic Basin Conference on Chemistry 2026

December 6-9, 2026

Rio de Janeiro

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

IPBC Asia 2026

November 17-19, 2026

Tokyo

Conference

Broad's 3rd Annual Biotech IP Summit

November 10, 2026

Cambridge

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP